Long-term effects of intravenous iloprost in patients with idiopathic pulmonary arterial hypertension deteriorating on non-parenteral therapy.
Standard
Long-term effects of intravenous iloprost in patients with idiopathic pulmonary arterial hypertension deteriorating on non-parenteral therapy. / Knudsen, Lars; Schurawlew, Alexander; Nickel, Nils; Tiede, Henning; Ghofrani, Hossein A; Wilkens, Heinrike; Ewert, Ralf; Halank, Michael; Klose, Hans; Bäzner, Carlos; Behr, Jürgen; Hoeper, Marius M.
in: BMC PULM MED, Jahrgang 11, 2011, S. 56.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Long-term effects of intravenous iloprost in patients with idiopathic pulmonary arterial hypertension deteriorating on non-parenteral therapy.
AU - Knudsen, Lars
AU - Schurawlew, Alexander
AU - Nickel, Nils
AU - Tiede, Henning
AU - Ghofrani, Hossein A
AU - Wilkens, Heinrike
AU - Ewert, Ralf
AU - Halank, Michael
AU - Klose, Hans
AU - Bäzner, Carlos
AU - Behr, Jürgen
AU - Hoeper, Marius M
PY - 2011
Y1 - 2011
N2 - The majority of patients with idiopathic pulmonary arterial hypertension (IPAH) in functional classes II and III are currently being treated with non-parenteral therapies, including endothelin receptor antagonists (ERA), phosphodiesterase (PDE)-5 inhibitors, inhaled iloprost or combinations of these substances. If these treatments fail, current guidelines recommend the addition of parenteral prostanoid therapy. There is, however, limited evidence for the efficacy of parenteral prostanoids when added to combinations of non-parenteral therapies.
AB - The majority of patients with idiopathic pulmonary arterial hypertension (IPAH) in functional classes II and III are currently being treated with non-parenteral therapies, including endothelin receptor antagonists (ERA), phosphodiesterase (PDE)-5 inhibitors, inhaled iloprost or combinations of these substances. If these treatments fail, current guidelines recommend the addition of parenteral prostanoid therapy. There is, however, limited evidence for the efficacy of parenteral prostanoids when added to combinations of non-parenteral therapies.
KW - Adult
KW - Humans
KW - Male
KW - Female
KW - Middle Aged
KW - Treatment Outcome
KW - Survival Analysis
KW - Retrospective Studies
KW - Administration, Oral
KW - Drug Therapy, Combination
KW - Injections, Intravenous
KW - Hypertension, Pulmonary/drug therapy
KW - Iloprost/administration & dosage/therapeutic use
KW - Phosphodiesterase Inhibitors/therapeutic use
KW - Receptors, Endothelin/antagonists & inhibitors
KW - Vasodilator Agents/administration & dosage/therapeutic use
KW - Adult
KW - Humans
KW - Male
KW - Female
KW - Middle Aged
KW - Treatment Outcome
KW - Survival Analysis
KW - Retrospective Studies
KW - Administration, Oral
KW - Drug Therapy, Combination
KW - Injections, Intravenous
KW - Hypertension, Pulmonary/drug therapy
KW - Iloprost/administration & dosage/therapeutic use
KW - Phosphodiesterase Inhibitors/therapeutic use
KW - Receptors, Endothelin/antagonists & inhibitors
KW - Vasodilator Agents/administration & dosage/therapeutic use
U2 - 10.1186/1471-2466-11-56
DO - 10.1186/1471-2466-11-56
M3 - SCORING: Journal article
VL - 11
SP - 56
JO - BMC PULM MED
JF - BMC PULM MED
SN - 1471-2466
ER -